Broome Oncology

Liver Cancer News

Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer (February 15, 2018)

CancerConnect News:  According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib).1 About... Continue Reading

Opdivo Precision Cancer Medicine Improves Outcomes in Advanced Liver Cancer (May 18, 2017)

Results from the CheckMate 040 clinical trial have been recently reported and found that Opdivo (nivolumab), an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates in patients with... Continue Reading

First New Drug for Liver Cancer in a Decade: Stivarga (May 8, 2017)

The US Food and Drug Administration (FDA) has expanded the indication for Stivarga (regorafenib) to now include treatment for patients with hepatocellular carcinoma (HCC) who have previously been treated with the drug Nexavar. Expansion of Stivarga, ‘s... Continue Reading

February: Gallbladder and Bile Duct Awareness Month (February 18, 2016)

Located underneath the liver, the gallbladder is responsible for the concentration and storage of bile which helps to digest the fats in food as they pass through the intestines. Bile is either released from the liver directly into ducts that carry it... Continue Reading

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (February 11, 2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency... Continue Reading

Infection with Hepatitis C Increases Risk of Cirrhosis (March 10, 2015)

People who are infected with the hepatitis C virus (HCV) have a higher risk for developing the liver disease cirrhosis, particularly within the first five years after infection. These findings were released in JAMA Internal Medicine. Cirrhosis, or late-stage... Continue Reading

Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen (July 31, 2014)

According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options with fewer side effects for most patients affected... Continue Reading

Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation (May 27, 2014)

The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press... Continue Reading

Coffee Cuts Risk of Liver Cancer (November 8, 2013)

Good news for coffee addicts—new research has found that regular coffee consumption can reduce the risk of liver cancer by 40 percent. In fact, the study—published in Clinical Gastroenterology and Hepatology—found that people who consume more than... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Latest Liver Cancer News By Stage


Hepatocellular Carcinoma Liver Cancer

Sorry, there are no articles available for this cancer stage.

More Hepatocellular Carcinoma Liver Cancer

Recurrent Liver Cancer

Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation (May 27, 2014)

The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press... Continue Reading

More Recurrent Liver Cancer

Screening/Prevention Liver Cancer

Infection with Hepatitis C Increases Risk of Cirrhosis (March 10, 2015)

People who are infected with the hepatitis C virus (HCV) have a higher risk for developing the liver disease cirrhosis, particularly within the first five years after infection. These findings were released in JAMA Internal Medicine. Cirrhosis, or late-stage... Continue Reading

Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen (July 31, 2014)

According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options with fewer side effects for most patients affected... Continue Reading

Coffee Cuts Risk of Liver Cancer (November 8, 2013)

Good news for coffee addicts—new research has found that regular coffee consumption can reduce the risk of liver cancer by 40 percent. In fact, the study—published in Clinical Gastroenterology and Hepatology—found that people who consume more than... Continue Reading

Statins Linked to Lower Risk of Liver Cancer in Hepatitis C (May 8, 2013)

People infected with chronic hepatitis C are less likely to develop liver cancer if they are taking statins (cholesterol-lowering drugs), according to the results of a study published in the Journal of Clinical Oncology.[1] The liver is the largest organ... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

More Screening/Prevention Liver Cancer

Stage IV Liver Cancer

Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation (May 27, 2014)

The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press... Continue Reading

Combination Chemotherapy Improves Survival with Biliary Tract Cancer (May 17, 2010)

According to the results of a Phase III clinical trial, treatment of locally advanced or metastatic biliary tract cancer with a combination of Gemzar® (gemcitabine) and cisplatin results in better survival and a lower risk of cancer progression than... Continue Reading

More Stage IV Liver Cancer

Stages I-III Liver Cancer

Combination Chemotherapy Improves Survival with Biliary Tract Cancer (May 17, 2010)

According to the results of a Phase III clinical trial, treatment of locally advanced or metastatic biliary tract cancer with a combination of Gemzar® (gemcitabine) and cisplatin results in better survival and a lower risk of cancer progression than... Continue Reading

More Stages I-III Liver Cancer